Addex Therapeutics Ltd (0QNV.L)
0QNV.L Stock Price Chart
Explore Addex Therapeutics Ltd interactive price chart. Choose custom timeframes to analyze 0QNV.L price movements and trends.
0QNV.L Company Profile
Discover essential business fundamentals and corporate details for Addex Therapeutics Ltd (0QNV.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
23.00
CEO
Timothy Mark Dyer
Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
0QNV.L Financial Timeline
Browse a chronological timeline of Addex Therapeutics Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Apr 2026
Upcoming earnings on 10 Nov 2025
Upcoming earnings on 1 Sept 2025
Earnings released on 9 Jun 2025
Earnings released on 18 Apr 2024
EPS came in at -CHF 0.01, while revenue for the quarter reached CHF 234.91K.
Earnings released on 19 Mar 2024
EPS came in at -CHF 0.03, while revenue for the quarter reached CHF 329.22K.
Earnings released on 31 Dec 2023
EPS came in at -CHF 0.03, while revenue for the quarter reached CHF 183.83K.
Earnings released on 30 Jun 2023
EPS came in at -CHF 0.04, while revenue for the quarter reached CHF 631.98K.
Earnings released on 31 Mar 2023
EPS came in at -CHF 0.04, while revenue for the quarter reached CHF 502.05K.
Earnings released on 31 Dec 2022
EPS came in at -CHF 0.06, while revenue for the quarter reached CHF 598.87K.
Earnings released on 30 Sept 2022
EPS came in at -CHF 0.09, while revenue for the quarter reached CHF 415.70K.
Earnings released on 30 Jun 2022
EPS came in at -CHF 0.19, while revenue for the quarter reached CHF 186.44K.
Earnings released on 31 Mar 2022
EPS came in at -CHF 0.15, while revenue for the quarter reached CHF 243.95K.
Earnings released on 31 Dec 2021
EPS came in at -CHF 0.13, while revenue for the quarter reached CHF 401.22K.
Earnings released on 30 Sept 2021
EPS came in at -CHF 0.11, while revenue for the quarter reached CHF 757.78K.
Earnings released on 30 Jun 2021
EPS came in at -CHF 0.14, while revenue for the quarter reached CHF 1.07M.
Earnings released on 31 Mar 2021
EPS came in at -CHF 0.08, while revenue for the quarter reached CHF 922.42K.
Earnings released on 31 Dec 2020
EPS came in at -CHF 0.08, while revenue for the quarter reached CHF 1.89M.
Earnings released on 30 Sept 2020
EPS came in at -CHF 0.12, while revenue for the quarter reached CHF 102.65K.
0QNV.L Stock Performance
Access detailed 0QNV.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.